Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 16/20 | 0.60 |
| ▸ | GAA | P10253 | 16/20 | 0.60 |
| ▸ | SI | P14410 | 16/20 | 0.60 |
| ▸ | MGAM2 | Q2M2H8 | 16/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | CBFB | Q13951 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509109 | 0.87 | CD44 (0.52) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4314003 | 0.79 | ACHE (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1170892 | 0.79 | MGAM (0.71) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL353891 | 0.79 | PARP1 (0.56) | MGAMGAASIMGAM2ESR1 | |
| Bromide SCHEMBL5318091 | 0.78 | PARP1 (0.55) | MGAMGAASIMGAM2ESR1 | |
| Bromide SCHEMBL11628987 | 0.78 | ACHE (0.45) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL8956217 | 0.76 | PSMD14 (0.39) | MGAMGAASIMGAM2TDP1 | |
| SCHEMBL17801881 | 0.76 | MGAM (0.53) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL3109602 | 0.76 | MGAM (0.60) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4692683 | 0.76 | MGAM (0.53) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3294732-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Gilead Sciences, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2017106552-A1 | POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AND COMBINATION THERAPY | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2016186967-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-6979683-B2 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-SYNTHELABO (FR) | 2005-12-27 | — | — | US | disclosed |
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-02-10 | — | — | US | disclosed |
| EP-1309594-B1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2004-12-15 | — | — | EP | disclosed |
| US-6794382-B2 | 6-OXO-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINE DERIVATIVES AS INHIBITORS OF ADP-RIBOSYLTRANSFERASE; CARDIOVASCULAR, IMMUNOLOGICAL, RESPIRATORY SYSTEM, AND NEURODEGENERATIVE DISORDER TREATMENT | SANOFI-SYNTHELABO (FR) | 2004-09-21 | — | — | US | disclosed |
| EP-1339719-B1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-20040029866-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2004-02-12 | — | — | US | disclosed |
| US-20030203893-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2003-10-30 | — | — | US | disclosed |
| EP-1339719-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | disclosed |
| EP-1309594-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002042306-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-05-30 | — | — | WO | disclosed |
| WO-2002012239-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, CYP3A7, HDAC7 | MGAM 4731/4885GAA 3044/4885SI 3115/4885 |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | MGAM 537/4885GAA 815/4885SI 722/4885 |
| US-20040029866-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, CBR1, NR3C1 | MGAM 4842/4885GAA 4076/4885SI 4468/4885 |
| US-20030203893-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, HRH4, CBR1 | MGAM 4774/4885GAA 3140/4885SI 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.